This site is optimised for modern browsers. For the best experience, please use Google Chrome, Mozilla Firefox, or Microsoft Edge.

AMGEN study investigating medication overuse headache opens at PRC: Newcastle


A new commercial research study to evaluate the efficacy and safety of erenumab in adults with chronic migraine and medication overuse headache has opened for recruitment at PRC: Newcastle. 

Chronic migraine is a condition in which migraine headaches and other symptoms become so frequent that they are present more days than not. Many people in this position end up using increasing amounts of painkillers, which can end up making the migraines worse and more frequent, a condition called medication overuse headache. 

Recently, a new type of preventative treatment for migraine has become available which blocks the action of a chemical called calcitonin gene-related peptide (CGRP), which is needed to generate the major migraine symptoms such as pain. 

The AMGEN trial is aiming to establish how effective this type of treatment is against chronic migraine, in cases where there is coexisting medication overuse headache. The hope is that through treatment with Erenumab, patients can become free of medication overuse headache and their migraines can be treated more effectively.

The trial will be led by Principal Investigator Dr Will Sedley at PRC: Newcastle. Dr Sedley said: “AMGEN is the second commercial research study investigating treatments for migraines to open at PRC: Newcastle this month and we have a further study currently in set-up. Our expertise in chronic headache disorders, coupled with our ability to consistently recruit participants into commercial research studies, is proving to be a draw to the life sciences industry looking to carry out research in this area.”

PRC: Newcastle is one of nine centres across the UK taking part in the AMGEN trial, which will recruit 650  people. Participants will be expected to complete 12 study visits and four telephone calls with a member of the study team over 59 weeks. 

Learn more about the AMGEN study and find out how to take part.